Zai Lab 配当と自社株買い
配当金 基準チェック /06
Zai Lab配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-0.05%
バイバック利回り
| 総株主利回り | -0.05% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
Seeking Alpha • May 13
Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached
Summary Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues, shifting focus to global pipeline assets. I assign zero intrinsic value to ZLAB's China business, given minimal "bottom line" contributions from blockbuster launches like Vyvgart and anticipated similar outcomes for KarXT. Zoci, a wholly owned Phase 3 oncology asset, is the key value driver for the company, with a modeled global rNPV near $1 billion and potential for multi-billion upside if expanded to 1L SCLC. I maintain a Speculative Buy rating on ZLAB, as its valuation hinges almost entirely on Zoci's clinical and commercial success, with risks from cash burn and competition. Read the full article on Seeking Alpha分析記事 • May 11
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Zai Lab Limited ( NASDAQ:ZLAB ), who've watched their investment drop 12% to US$18.60 in the...
ナラティブの更新 • May 01
ZLAB: Diversified Pipeline And DLL3 Partnerships Will Support Long-Term Expansion
The analyst price target for Zai Lab has been reduced by about $14 to $35, with analysts citing lower modeled revenue growth, modestly higher discount rates, and management's commentary on more modest 2026 top line expectations given pricing pressures and competition in China. Analyst Commentary Recent Street research on Zai Lab points to a more cautious stance on revenue growth and valuation, with several firms trimming their price targets while still recognizing areas of execution strength and pipeline potential.
ナラティブの更新 • Apr 16
ZLAB: Cautious China Outlook And Pipeline Progress Will Shape A Measured Re Rating
Analysts have lowered their average price targets on Zai Lab by several dollars, citing more cautious expectations for 2026 revenue growth. Management anticipates modest top line trends with pricing pressure and rising competition in China, which is reflected in slightly adjusted P/E assumptions and growth inputs.ナラティブの更新 • Apr 02
ZLAB: Mixed Coverage And Pipeline Progress Will Shape A Measured Re Rating
Analysts have trimmed their price targets on Zai Lab, and the model update now points to a fair value of $21.80. This reflects expectations for more modest revenue growth and profit margins, along with a higher future P/E multiple.
ナラティブの更新 • Mar 19
ZLAB: China Approvals And Oncology Pipeline Progress Will Support Future Upside Potential
Analysts have trimmed their price targets on Zai Lab by up to $18, reflecting more cautious assumptions on revenue growth and competitive pressures. At the same time, updated models incorporate a higher projected profit margin and a lower future P/E multiple.ナラティブの更新 • Mar 04
ZLAB: China Approvals And Pipeline Execution Will Support Future Upside Potential
Narrative Update The updated analyst price target for Zai Lab has moved down from $67.22 to $55.00 as analysts factor in more modest projected revenue growth, lower profit margins, a higher assumed discount rate, and recent Street research pointing to pricing pressure, competition in China, and adjustments to company models following management commentary. Analyst Commentary Recent Street research on Zai Lab shows a mix of recalibrated price targets and ongoing constructive views on execution and longer term growth prospects.ナラティブの更新 • Feb 17
ZLAB: Mixed Coverage And New Approvals Will Shape A Measured Re Rating
Analysts trimmed their price targets on Zai Lab by $3.03, reflecting updated fair value and P/E assumptions, as well as fresh views on the company following recent research coverage changes. Analyst Commentary Recent Street research on Zai Lab has sent a mixed message, with some optimism around longer term potential but also fresh caution on how the current share price lines up with execution risks and valuation assumptions.ナラティブの更新 • Feb 03
ZLAB: Fresh Coverage And Pipeline Progress Will Support A Re Rating
The updated analyst price target for Zai Lab moves to about US$23.45 from about US$28.14, as analysts factor in lower revenue growth assumptions and a lower future P/E multiple, partly offset by higher projected profit margins and supported by fresh coverage and a US$35 target from recent Street research. Analyst Commentary While the updated blended price target for Zai Lab sits around US$23.45, investor sentiment is being pulled in different directions.ナラティブの更新 • Jan 20
ZLAB: Pipeline And New China Approvals Will Drive Future Upside Potential
Analysts have nudged their fair value estimate for Zai Lab to US$67.22 per share, reflecting slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E following fresh coverage initiation and list changes in recent Street research. Analyst Commentary Street research on Zai Lab has been mixed recently, but the latest fair value update and fresh coverage suggest that some bullish analysts still see room for upside relative to current pricing.ナラティブの更新 • Jan 06
ZLAB: Pipeline Execution After Conviction List Removal Will Drive Upside Potential
Analysts have trimmed their fair value estimate for Zai Lab from US$74.00 to US$67.22, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples following its removal from a regional conviction list by a major broker. Analyst Commentary Goldman Sachs removed Zai Lab from its APAC Conviction List as part of a broader monthly review, which has prompted some investors to reassess expectations and risk appetite around the stock.ナラティブの更新 • Dec 20
ZLAB Removed From Conviction List Yet Future Pipeline Progress May Re-Rate Shares
Analysts have cut their price target on Zai Lab from approximately $39 to about $28, reflecting a materially lower growth outlook and higher perceived risk, as evidenced by its recent removal from a major APAC conviction list. Analyst Commentary Bearish analysts have interpreted the removal of Zai Lab from a major APAC conviction list as a signal that the company may face a more challenging path to justifying a premium valuation, particularly given rising competition and execution uncertainties in its pipeline and commercialization strategy.ナラティブの更新 • Dec 06
ZLAB: Diversified Pipeline Is Expected To Drive Long-Term Market Expansion
Narrative Update on Zai Lab Analysts have moderately lowered their price target on Zai Lab to approximately $49.49, reflecting more conservative assumptions for revenue growth and profit margins, along with the stock’s recent removal from a key regional conviction list. Analyst Commentary Recent research updates on Zai Lab have prompted a more nuanced view of the company’s risk and reward profile, with analysts highlighting both supportive fundamentals and execution challenges that could influence the stock’s re-rating trajectory.ナラティブの更新 • Nov 22
ZLAB: Pipeline Diversification And Ongoing Partnerships Will Support Long-Term Market Expansion
Zai Lab's analyst price target has been revised downward from approximately $53.40 to $49.49. Analysts cite concerns over slowing revenue growth and narrowing profit margins.分析記事 • Nov 09
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Zai Lab Limited ( NASDAQ:ZLAB ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...分析記事 • Nov 07
Analyst Forecasts Just Became More Bearish On Zai Lab Limited (NASDAQ:ZLAB)
Market forces rained on the parade of Zai Lab Limited ( NASDAQ:ZLAB ) shareholders today, when the analysts downgraded...ナラティブの更新 • Nov 07
ZLAB: Future Product Launches Will Drive Broader Market Reach And Patient Access
Analysts have lowered their price target for Zai Lab from approximately $55.41 to $53.40. They cite adjustments in key financial projections and the company's recent removal from a major conviction list as supporting factors.分析記事 • Nov 06
Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders that were waiting for something to happen have been dealt a blow with a...分析記事 • Oct 05
Is Zai Lab (NASDAQ:ZLAB) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブの更新 • Sep 23
Expanding China Healthcare And Global Pipelines Will Broaden Patient Options
Despite encouraging Phase III trial data for bemarituzumab in gastric cancer, which bolsters near-term commercial outlooks and regulatory momentum in China, Zai Lab’s consensus analyst price target saw only a slight downward adjustment from $56.31 to $55.41. Analyst Commentary Positive Phase III FORTITUDE-101 trial data for bemarituzumab in first-line FGFR2b+ gastric cancer.分析記事 • Jun 16
Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33%
Zai Lab Limited ( NASDAQ:ZLAB ) shares have had a really impressive month, gaining 33% after a shaky period beforehand...
新しいナラティブ • Apr 30
New VYVGART And Pipeline Advances Will Expand Global Markets
Strong revenue growth is expected due to robust product launches and pipeline innovations, with profitability anticipated through cost optimization and operational efficiencies.Seeking Alpha • Mar 20
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
Summary ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB’s main growth drivers. ZLAB’s ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China. ZLAB’s balance sheet is pretty solid, with close to 2.4 years of runway, and aiming towards profitability by yearend 2025. ZLAB’s valuation is higher than when I first covered it. New trade risks between the US and China also exist, but I remain bullish at these levels. Read the full article on Seeking Alpha分析記事 • Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders have had their patience rewarded with a 31% share price jump in the last...分析記事 • Jan 20
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Zai Lab Limited ( NASDAQ:ZLAB ) is a stock worth...Seeking Alpha • Dec 26
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Summary Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future. Zai Lab's unique market position and strong pipeline make it a compelling investment for those with high risk tolerance. Read the full article on Seeking Alpha分析記事 • Nov 15
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
There's been a notable change in appetite for Zai Lab Limited ( NASDAQ:ZLAB ) shares in the week since its...分析記事 • Sep 28
Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Zai Lab Limited ( NASDAQ:ZLAB ) shares have continued their recent momentum with a 26% gain in the last month alone...分析記事 • Sep 23
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 12
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Key Insights Zai Lab will host its Annual General Meeting on 18th of June Salary of US$868.5k is part of CEO Samantha...分析記事 • May 14
Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Apr 16
A Risky Bet: Zai Lab's Uncertain Future
Summary Zai Lab offers a weaker value proposition for investors looking to bet on Chinese biotech due to its pure license in approach, limiting its potential to tap into global market. Its key products have shown a slow-down in 2023 and is facing increased competition. There is limited excitement in the current pipeline, as competitors have already taken the lead in the development timeline. The company is overvalued because it is trading at a similar P/S ratio to its peers, even though it has weaker quality in several key aspects. Read the full article on Seeking Alpha分析記事 • Mar 29
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Unfortunately for some shareholders, the Zai Lab Limited ( NASDAQ:ZLAB ) share price has dived 29% in the last thirty...分析記事 • Mar 24
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...決済の安定と成長
配当データの取得
安定した配当: ZLABの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: ZLABの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Zai Lab 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (ZLAB) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Biotechs) | 2.4% |
| アナリスト予想 (ZLAB) (最長3年) | 0% |
注目すべき配当: ZLABは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: ZLABは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: ZLABの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: ZLABが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 23:50 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Zai Lab Limited 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。34
| アナリスト | 機関 |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Bo Li | BofA Global Research |